SRPT Stock Catalyst Calendar

The 31st Annual Congress of the World Muscle Society will be taking place. Location:Hiroshima Japan -------- Poster presentation of functional and safety outcomes up to 3 years post-infusion of delandistrogene moxeparvovec in Duchenne muscular dystrophy from the EMBARK study. Location:Hiroshima Japan -------- Poster presentation of micro-dystrophin expression and safety data for delandistrogene moxeparvovec in 2-3-year-old Duchenne muscular dystrophy patients from the ENDEAVOR and ENVOL studies. Location:Hiroshima Japan -------- Poster presentation of pooled safety analysis across Phase 1 to Phase 3 clinical trials of delandistrogene moxeparvovec in Duchenne muscular dystrophy. Location:Hiroshima Japan -------- Poster presentation of efficacy and safety results of early intervention with delandistrogene moxeparvovec in DMDMDX mice. Location:Hiroshima Japan -------- Poster presentation of Phase 3 results and post hoc analysis comparing golodirsen and casimersen versus placebo in Duchenne muscular dystrophy (ESSENCE). Location:Hiroshima Japan -------- Poster presentation on the TRAILHEAD open-label study evaluating long-term safety and efficacy of forazapadin (SAT-3247) in adults with Duchenne muscular dystrophy (DMD). Location:Hiroshima Japan -------- Poster presentation on translating a regenerative index from preclinical to human settings including quantification of progressive muscle degeneration and treatment response. Location:Hiroshima Japan -------- Poster presentation on the rationale and design of a safety tolerability and long-term efficacy study of forazapadin (SAT-3247) in facioscapulohumeral muscular dystrophy (FSHD).